

| Guideline Page and Request | Panel Discussion/References | Institution Vote | | | |
|---|--|------------------|----|---------|--------|
| | | YES | NO | ABSTAIN | ABSENT |
| <p>SC-F Internal request:</p> <p>Comment to consider the inclusion of combination varenicline + bupropion as an option for heavy smokers ≥ 20 cigarettes/day or FTND (Fagerstrom Test for Nicotine Dependence) ≥ 6.</p> | <p>Based on the review of the data in the noted references, the panel consensus was to include varenicline + bupropion (long-acting) as a pharmacotherapy option. This is a category 2A, other recommended regimen.</p> <p>References:</p> <ul style="list-style-type: none"> Cinciripini PM, Minnix JA, Green CE, et al. An RCT with the combination of varenicline and bupropion for smoking cessation: clinical implications for front line use. <i>Addiction</i>, 2018;113(9):1673-1682. Ebbert JO, Hatsukami DK, Croghan IT, et al. Combination varenicline and bupropion SR for tobacco-dependence treatment in cigarette smokers: a randomized trial. <i>JAMA</i>, 2014;311(2):155-163. | 12 | 0 | 0 | 16 |